Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Market Challenges High Cost of Treatment Limits Adoption Across Lower-Income Populations and Health Systems Despite clinical efficacy, the high cost of GLP-1 therapies remains a significant barrier to widespread adoption
Higher-dose versions like Wegovy and Zepbound have received FDA approval specifically for obesity, fueling a market expected to boom from $2.8 billion in 2022 to over $100 billion by 2030
What Is Saline (0.9% Sodium Chloride)
With technology like phones and video games, its easy to spend a lot of time sitting down instead of being active
Prescribing them fits within an integrative psychopharmacology framework that takes seriously the interconnections between metabolic and mental health
US$ 24.01
US$ 20.76
US$ 29.80
US$ 25.46
US$ 23.94
US$ 20.70
